337 related articles for article (PubMed ID: 17655510)
1. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
[TBL] [Abstract][Full Text] [Related]
2. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
[TBL] [Abstract][Full Text] [Related]
3. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.
Lawrence DB; Ragucci KR; Long LB; Parris BS; Helfer LA
J Manag Care Pharm; 2006; 12(6):466-71. PubMed ID: 16925454
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.
Jermendy G; ; Erdesz D; Nagy L; Yin D; Phatak H; Karve S; Engel S; Balkrishnan R
Health Qual Life Outcomes; 2008 Oct; 6():88. PubMed ID: 18976457
[TBL] [Abstract][Full Text] [Related]
5. Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.
Herman WH; Buse JB; Arakaki RF; Dungan KM; Jiang HH; Jacobson JG; Fahrbach JL
Endocr Pract; 2011; 17(4):563-7. PubMed ID: 21550959
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
[TBL] [Abstract][Full Text] [Related]
7. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
Bell DS; Ovalle F
Endocr Pract; 2000; 6(4):293-5. PubMed ID: 11242605
[TBL] [Abstract][Full Text] [Related]
8. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.
Rendell MS; Glazer NB; Ye Z
J Diabetes Complications; 2003; 17(4):211-7. PubMed ID: 12810245
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
11. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
12. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
13. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
[TBL] [Abstract][Full Text] [Related]
14. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.
Eurich DT; Simpson SH; Majumdar SR; Johnson JA
Pharmacotherapy; 2005 Jun; 25(6):810-6. PubMed ID: 15927899
[TBL] [Abstract][Full Text] [Related]
15. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
16. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
18. Oral antidiabetic medication adherence and glycemic control in managed care.
Rozenfeld Y; Hunt JS; Plauschinat C; Wong KS
Am J Manag Care; 2008 Feb; 14(2):71-5. PubMed ID: 18269302
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.
Asche CV; McAdam-Marx C; Shane-McWhorter L; Sheng X; Plauschinat CA
Drugs Aging; 2008; 25(7):611-22. PubMed ID: 18582148
[TBL] [Abstract][Full Text] [Related]
20. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.
Phung OJ; Sobieraj DM; Engel SS; Rajpathak SN
Diabetes Obes Metab; 2014 May; 16(5):410-7. PubMed ID: 24205921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
